

1 **Vent-Lock: A 3D Printed Ventilator Multiplexer to Enhance the Capacity of Treating**  
2 **Patients with COVID-19**

3  
4 Helen Xun<sup>1</sup>, Christopher Shallal<sup>2</sup>, Justin Unger<sup>3</sup>, Runhan Tao<sup>2</sup>, Alberto Torres<sup>3</sup>, Michael  
5 Vladimirov<sup>3</sup>, Jenna Frye<sup>4</sup>, Mohit Singhal<sup>5</sup>, Brockett Horne<sup>4</sup>, Pooja Yesantharao<sup>1</sup>, Bo Soo Kim<sup>1</sup>,  
6 Broc Burke<sup>6</sup>, Michael Montana<sup>6</sup>, Michael Talcott<sup>6</sup>, Bradford Winters<sup>1</sup>, Margaret Frisella<sup>6</sup>,  
7 Bradley Kushner<sup>6</sup>, Justin M. Sacks<sup>6</sup>, James K. Guest<sup>3,\*</sup>, Sung Hoon Kang<sup>5,\*</sup>, Julie Caffrey<sup>1,\*</sup>

8  
9 <sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, 21231

10 <sup>2</sup>Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21231

11 <sup>3</sup>Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD,  
12 21218

13 <sup>4</sup>Maryland Institute College of Art, Baltimore, MD, 21217

14 <sup>5</sup>Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218

15 <sup>6</sup>Washington University in St. Louis School of Medicine, St. Louis, Missouri, 63130

16 \*To whom correspondence should be addressed: [jkguest@jhu.edu](mailto:jkguest@jhu.edu), [shkang@jhu.edu](mailto:shkang@jhu.edu),  
17 [jcaffre5@jhmi.edu](mailto:jcaffre5@jhmi.edu)

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33 **ABSTRACT:** Mechanical ventilators are essential to patients who become critically ill from  
34 acute respiratory distress syndrome (ARDS), and shortages have been reported due to the novel  
35 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We utilized cost-effective, on-  
36 demand 3D printing (3DP) technology to produce critical components for a novel ventilator  
37 multiplexer system, Vent-Lock, to split one ventilator or anesthesia gas machine between two  
38 patients. FloRest, a novel 3DP flow restrictor, provides clinicians control of tidal volumes and  
39 positive end expiratory pressure (PEEP), using the 3DP manometer adaptor to monitor pressures.  
40 We tested the ventilator splitter circuit in simulation centers between artificial lungs and used an  
41 anesthesia gas machine to successfully ventilate two swines. As one of the first studies to  
42 demonstrate splitting one anesthesia gas machine between two swines, we present proof-of-  
43 concept of a *de novo*, closed, multiplexing system, with flow restriction for individualized patient  
44 therapy. Our studies underscore that while possible, ventilator multiplexing is a complicated  
45 synergy between machine settings, circuit modification, and patient monitoring. Consequently,  
46 ventilator multiplexing is reserved only as a last emergency resource, by trained clinicians and  
47 respiratory therapists with ventilator operative experience.

48

49

50

51

52

53

## 54 INTRODUCTION

55           The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a  
56 global pandemic resulting in rapid depletion of resources necessary to care for critically ill  
57 patients, such as mechanical ventilators and their associated parts. Mechanical ventilators are  
58 critical for the treatment of approximately 5-10% of patients with coronavirus disease (COVID-  
59 19) who become critically ill from acute respiratory distress syndrome (ARDS)<sup>1</sup>. In the face of  
60 the COVID-19 pandemic, it is estimated that there is a global ventilator shortage of 880,000<sup>2</sup>.  
61 This shortage may disproportionately affect developing countries who suffer from lack of  
62 medical infrastructure and resources<sup>3</sup>, historically resulting in higher mortality rates in  
63 pandemics such as the Spanish Flu<sup>4</sup>. For example, the continent of Africa has limited ventilator  
64 capacity, with only 2,000 ventilators across 41 countries<sup>5</sup>. This capacity deficit is further  
65 worsened by the increased need due to the COVID-19 pandemic.

66           Ventilator shortages occur in resource-rich countries as well. Previous disasters and  
67 current projections suggest that hospitals may be operating at 120-160% capacity in the face of a  
68 pandemic or national disaster<sup>6</sup>. Projections suggest that if 20% of the United States population is  
69 infected with the virus, there will be significant deficiencies in intensive care unit beds and  
70 mechanical ventilators<sup>6,7</sup>. Furthermore, given the potential for a second wave of infection,  
71 epidemiologists predict that if countries continue to lift restrictions used to slow the spread of the  
72 virus too early, then a second global peak may result in a further shortage of medical supplies<sup>8</sup>,  
73 ventilators and ventilator associated parts. The Society of Critical Care Medicine shared that  
74 clinicians continue to report ventilator shortages in summer of 2020, including 53% of 587  
75 surveyed ICU clinicians did not have enough ventilators and had to use non-standard ventilators  
76 or non-invasive devices, and a small percentage declined care due to shortage of ventilators, or

77 placed two patients on one ventilator<sup>9</sup>. Consequently, there is a critical need to address urgent  
78 ventilator shortages in the face of the COVID-19 pandemic.

79 While the introduction of more ventilators, either *de novo* or commercial, could solve the  
80 urgent medical needs arising from the COVID-19 pandemic, this solution represents a theoretical  
81 ideal that cannot be achieved given the current monetary, time, hospital infrastructure, limited  
82 scaling and production capacity, and supply chain constraints<sup>10,11</sup>, further exacerbated by lack  
83 of standardization of parts across brands<sup>12</sup>. An alternative strategy to quickly increase ventilator  
84 capacity as an immediate step in urgent settings is to “split” or multiplex ventilators and  
85 anesthesia gas machines. Ventilator multiplexing allows the usage of one machine to ventilate  
86 multiple patients and effectively increases the clinical capacity to support urgent needs.

87 The concept of using one ventilator to support multiple patients during a disaster surge  
88 was first published in 2006 by Neyman *et al.*<sup>13</sup>, who reported that four patients could be  
89 supported for 12 hours using ventilator equipment and tubing. However, these *in vitro* studies  
90 were restricted to patients with similar body habitus and lung compliances. Despite these study  
91 limitations, it introduced ventilator multiplexing as a potential solution for emergency situations.  
92 In 2017, this proof-of-concept was demonstrated in actual patients during the 2017 Las Vegas  
93 shooting<sup>14</sup> when a physician supported multiple patients on a single ventilator as a temporary  
94 emergency situation until more resources became available. The ability to multiplex ventilators  
95 is valuable for global preparedness mechanisms to promptly increase ventilator capacity as an  
96 immediate response for disasters, such as trauma surges, natural disasters, or in military  
97 frontlines.

98 Emergency use of ventilator multiplexing is dependent on the dynamic lung states of the  
99 patients, including associated lung compliances and airway resistances that drive airflow

100 balance. In the evolving pathologic state of COVID-19 patients with ARDS, an interdependent  
101 ventilation system poses many safety concerns. The Society of Critical Care Medicine and other  
102 societies in respiratory care issued a joint statement<sup>15</sup> summarizing main concerns with  
103 ventilator multiplexing<sup>16</sup>, including the inability to independently monitor and control  
104 ventilation parameters (volumes, pressures, rates) critical for ARDS treatment, thus risking  
105 adverse outcomes such as underventilation, or ventilator induced lung injury (VILI) such as  
106 barotrauma. Additional concerns include ventilator alarm management, disrupted balance of  
107 ventilation if a patient has spontaneous breathing, sudden deterioration, kink in the tubing, and  
108 viral contamination if breathing circuits between patients are mixed, or the circuit becomes open.

109 While these barriers exist, they are not insurmountable for emergency ventilator  
110 multiplexing. For example, recent engineering solutions have emerged using off-the-shelf  
111 medical components that mitigate concerns in ventilator multiplexing by volume or pressure  
112 control, and monitoring<sup>17</sup>. It is optimistic that these circuits present potential solutions for  
113 ventilator shortages in emergency situations; however, deployment can be limited due to  
114 unstable supply chains that make these off-the-shelf medical components difficult to acquire<sup>18</sup>,  
115 even in developed countries up to six months from inciting events<sup>19</sup>. Consequently, rapid  
116 production of *de novo* ventilator multiplexing solutions are investigated to further address these  
117 barriers.

118 Among multiple modalities for *de novo* manufacturing to address medical equipment  
119 shortages, 3D printing has come to the forefront during the COVID-19 pandemic to address  
120 critical shortages<sup>12,20</sup>. 3D printing is a type of additive manufacturing that has emerged in the  
121 past decades as a cost-effective, rapid on-demand production modality with broad applications  
122 due to its ability to produce intricate and complex geometries from computer-aided designs

123 without tooling and expensive machines<sup>21</sup>. 3D printing enables faster design and manufacturing  
124 processes<sup>22</sup>, so that it can be utilized in emergency situations to fill gaps in the supply chain<sup>23</sup>.  
125 Specifically, in reference to COVID-19, there have been multiple shortages in ventilator  
126 associated equipment and valves, leading healthcare providers to look into different avenues of  
127 manufacturing to address the gap in the supply<sup>20</sup>. Ventilator splitter products which primarily  
128 use commercial medical equipment may have limited or unreliable supply<sup>17</sup> in urgent situations.  
129 We address urgent medical needs arising from unstable supply chains by using 3D printing to  
130 rapidly and cost-effectively prototype and test components of our ventilator splitter circuit using  
131 biocompatible and sterilizable materials.

132         In this study, we present Vent-Lock, a *de novo*, ventilator multiplexing system that  
133 addresses major concerns with ventilator splitting, and is rapidly produced via 3D printing, thus  
134 tapping into a broad international production infrastructure largely unaffected by the pandemic.  
135 The Vent-Lock breathing circuit provides clinicians with a way to control, manage and monitor  
136 patients split on one ventilator; circuit components allow for the change in individual tidal  
137 volumes and positive end expiratory pressure (PEEP), pressure monitoring, and minimized back  
138 flow and risk of contamination. Our novel, air-tight, 3DP flow restrictor (FloRest) is designed to  
139 provide clinicians with precise control of tidal volumes. We validate the use of Vent-Lock  
140 FloRest for both ventilators and anesthesia gas machines, successfully ventilating simulated  
141 patients with mismatched lung compliances. Furthermore, we ventilated two swine safely with  
142 Vent-Lock, demonstrating the device's ability to both safely multiplex patients and to evolve  
143 anesthesia gas machines (which are more commonly available in developing countries as  
144 compared to ventilators) with increased ventilation settings. We share differences in multiplexing  
145 of anesthesia gas machines and ventilators, and the impact of ventilator control mode (volume

146 control versus pressure control) on multiplexing, and additional challenges. The novel, *de novo*,  
147 3DP Vent-Lock circuit and FloRest is well positioned to rapidly increase capacity of mechanical  
148 ventilators to provisionally meet ventilator shortages due to the COVID-19 pandemic and future  
149 pandemics and disasters.

150

## 151 **RESULTS**

### 152 ***Vent-Lock 1+n(1) circuit and components***


153 We validated a 1+n(1) system which can split one ventilator between one standard patient  
154 and one or potentially more variable patients (Fig.1). The standard patient ideally has the lowest  
155 lung compliance and has minimal components in the circuit to establish low resistance allowing  
156 the ventilator to maintain standard function. The standard patient will be ventilated at pressure  
157 settings unaltered from that delivered by the ventilator. Additional patients (n) added to the  
158 circuit are considered variable patients and can have their tidal volumes and PEEP altered by  
159 circuit components. This paper demonstrates use of a ventilator splitter adjusting for 1 control  
160 and n=1 variable patients. The 1+n(1) split contains Vent-Lock 3DP parts and commercial parts  
161 (Fig. 1). We 3D printed the splitters and the flow restrictors (needle valves). The other parts  
162 including the one-way check valves, the filters and the PEEP valves were all commercial parts  
163 (fig. S1). The Vent-Lock circuit was designed to be closed circuit and leak-free to minimize risk  
164 of aerosolizing viral particles into the surrounding environment.

165

### 166 ***Vent-Lock 3DP Flow Restrictor (FloRest)***

167 The Vent-Lock 3DP flow restrictor (Vent-Lock FloRest) is a flow restrictor based on a  
168 needle control valve design optimized for low flow rates to offer clinicians robust control over a

169 range appropriate for human ventilation. Vent-Lock FloRest was designed to address the  
170 following concerns regarding ventilator “splitting” (15): 1. Volumes would distribute unevenly



171  
172 **Fig. 1. Vent-Lock ventilator multiplexing 1+n(1) circuit and 3DP components.** Our 1+n(1) circuit proposes  
173 having a standard patient with minimal features, thus are ventilated per ventilator settings. Additional patients added  
174 to the circuit will be considered n(1), and will have variable flow and PEEP as controlled by circuit components.  
175 Please note that all patients, regardless of standard or variable, have one-way (check) valves and filters.


176  
177 between patients, 2. PEEP would be difficult to manage per patient, 3. Tidal volumes would be  
178 difficult to manage per patient and 4. Adjustment or discontinuation of ventilation to one patient  
179 would alter breathing dynamics to other patients.

180 The goal of FloRest (Fig. 2A) was to allow the clinician to modify the flow rate of air  
181 being delivered to the patient, thus providing ranges of clinical tidal volumes and PEEPs with  
182 control sensitivity and a reliable linear relationship between closure and flow rate, tidal volume,




183 and pressures. The design emphasizes the minimization of build time and volume by reducing  
184 support material use and complex structures for consistent and higher quality printing. These

185  
186 (A)



196 (B)



197 **Figure 2. Design and performance of 3DP Flow Restrictor (FloRest).** (A) Vent-Lock 3DP Flow Restrictor  
198 (FloRest) contains three components. The O-ring between the cap and full-height threaded needle interface at the top  
199 of the chamber to maintain air-tight seals. Both ends of Vent-Lock FloRest are male ISO fittings to ensure

200 connection to ventilator tubing. (B) Testing with a ventilator on pressure control using simulation lungs at varying  
201 compliances demonstrates that Vent-Lock FloRest provides more control options than commercial ball valves and  
202 gate valves, characterized by more available data points corresponding with different tidal volumes delivered.

203

204 considerations allowed for an air-tight and leak-proof design (fig. S2) and utilization of  
205 biocompatible materials that can withstand extended exposure to warm humidified air and  
206 sterilizing autoclave environment. Using a particle counter, post and pre-autoclave tests  
207 demonstrate significant micron particle reduction after autoclaving (fig. S3).

208         The needle valve utilizes change in flow momentum, flow path geometry and orifice flow  
209 design concepts allowing easy control of flow rate vs pressure drop ratio (i.e. flow coefficient)  
210 compared to gate and ball valve concepts (more binary valve concepts). It operates with less total  
211 pressure drop over the flow control ranges than typical globe valve concepts. The threading  
212 allows for control over the flow rates and offers the clinician the ability to make fine adjustments  
213 to the flow within the range of control. We used a gasket-inspired design featuring an O-ring  
214 (E1000-212/AS568-212, O-Rings EPDM, FDA EPDM, Marco Rubber & Plastics, Seabrook,  
215 New Hampshire, USA) seated between the needle and chamber to ensure airtightness, thus  
216 reducing the risk of aerosolizing the virus into the surrounding environment. Final features of  
217 FloRest (Fig. 2A) included sealing to the external environment using unthreaded upper needle  
218 shafts for smoother interfaces between cap O-ring and needle during operation of valve and a  
219 delayed start in needle threading to provide earlier range of flow control and to allow for safe  
220 operation of valve by preventing full occlusion of flow to patient by clinician.

221         The FloRest has advantages compared with commercial valves in terms of the  
222 controllability, biocompatibility, and sterilizability. The FloRest had similar range of control  
223 compared to commercial gate valves (#P20034 PVC SCH 40 ½-in FNPT Ball Valve; G300 Lead

224 Free Brass Gate Valve, American Valve, Greensboro, North Carolina, USA) (Fig. 2B). However,  
225 the Vent-Lock FloRest provides more control options than commercial valves, characterized by  
226 more points available for the clinician to choose from corresponding to different tidal volumes  
227 delivered. Furthermore, FloRest is produced with biocompatible, nontoxic materials that can be  
228 safely sterilized, as compared to commercial ball valves with untested biocompatibility and  
229 unknown sterilization protocols. Vent-Lock FloRest can be produced at an estimated \$3.50 per  
230 device in 3-hour 40 min print and process time via fused deposition modeling (FDM) (e3d,  
231 BigBox3D Ltd, Oxfordshire, UK; Little Monster, Tevo 3D Electronic Technology Co. Ltd,  
232 Zhanjiang, China) using PETG (PETG 3D Printer Filament, FilaMatrix, Virginia, USA). With  
233 stereolithography (SLA; Form 2, Form 3, or Form 3B, Formlabs), it costs approximately \$25,  
234 and 16 hours production time with a 50 micron build layer height resolution, using surgical guide  
235 resin (Surgical Guide, Formlabs). We demonstrate that the FloRest is leak proof through air  
236 volume testing (fig. S2).

237

### 238 ***Vent-Lock 3DP Flow Restrictor (FloRest) control of tidal volumes and PEEP***

239 We tested the use of Vent-Lock FloRest in the Johns Hopkins Medicine Simulation  
240 Center (JHMSC) to confirm the following: 1) Allowing volumes to be distributed evenly  
241 between patients, 2) variable patient control of PEEP, 3) variable patient tidal volume control  
242 and 4) changes in the variable patient breathing settings does not alter breathing dynamics to the  
243 standard patient.

244 We tested the Vent-Lock multiplexing system using a 1+1 split patient circuit (Fig. 1).  
245 We used one ventilator (Puritan Bennett 840 Ventilator System, Avante Health Solutions) to  
246 ventilate two patients with different lung compliances of 20 cmH<sub>2</sub>O and 50 cmH<sub>2</sub>O. We first  
247 tested using a pressure control mode, with inspiratory pressures set at 25 cmH<sub>2</sub>O (additional

248 ventilator settings available in Table S2). The Vent-Lock FloRest allowed adjustment of tidal  
249 volumes delivered to patients between  $7\frac{3}{4}$  turns to  $9\frac{7}{8}$  turns (fully closed), corresponding to  
250 21.5% of tidal volume control range and  $2\frac{1}{8}$  turning range control (Fig. 3A). It allowed control  
251 of 85.7% of the total range of delivered tidal volumes (compared to initial variable patient tidal  
252 volume) with negligible change in tidal volume delivery to the standard patient (range: 99.86%  
253 and 103.2% initial standard patient tidal volume, mean:  $102.1\% \pm 0.98\%$ ). We note that the total  
254 expiratory volume reported by the ventilator trends with tidal volume delivered to the variable  
255 patient (Fig. 3A) and the peak inspiratory pressures (PIP) of the variable patient and ventilator  
256 peak inspiratory volumes also correspondingly decrease with decreases in tidal volume (Fig.  
257 3B,C), while peak inspiratory volumes remain stable for the standard patient and peak end  
258 expiratory volumes remain stable for both patients during these changes.


259 We repeated Vent-Lock 1+1 multiplexing patient circuit with the ventilator on volume  
260 control mode to deliver a total of 2L of volume, corresponding to approximately 600 mL of tidal  
261 volume per patient (additional ventilator settings available in table S1). We note that turning of  
262 FloRest on the variable patient resulted in decrease of both tidal volumes and PIP (Fig. 4A,B).  
263 However, this was accompanied with an increase in tidal volume delivery and PIP to the  
264 standard patient (Fig. 4A,B), with relatively stable ventilator reported average pressures (Vent  
265  $P_{avg}$ ) and PEEP (Fig. 4B). Thus, unlike in pressure control mode where control of delivery to the  
266 variable patient was independent of the standard patient, flow restriction in the volume control  
267 mode resulted in the modification of the ratio of tidal volumes delivered (Fig. 4C,  
268 standard/variable patient tidal volume ratios).

269


270

271

272



(C)



273

(B)




Fig. 3. Pressure control mode: testing of Vent-Lock ventilator multiplexor with a ventilator on pressure control mode ventilating two simulated patients with different lung compliances. (A)

When used with a ventilator on pressure control,

283

284

285

286

287

288

289

290


291

292

293

Vent-Lock FloRest is capable of controlling tidal volumes delivered to the variable patient per turn, with no change to tidal volumes delivered to the standard patient. (B) PIP of the standard patient remains stable, despite changing PIP of the variable patient. Using a ventilator on pressure control, we determine the changes in standard and variable patient breathing pressures with closure of the Vent-Lock FloRest, and the ventilator reported pressures. The positive inspiratory pressure (PIP) of the variable patient decreases with closure, while the standard patient PIP, and ventilator reported average breathing pressures ( $P_{avg}$ ), and PEEP remain constant. We do note an increase in the ventilator reported PIP. (C) With the ventilator on pressure control, changes to tidal volume delivered to patients using Vent-Lock FloRest demonstrates a corresponding change in peak inspiratory pressures (PIP).

294  
295  
296  
297  
298



300

301

302 **Figure 4. Volume control mode: testing of Vent-Lock ventilator multiplexer with a ventilator or anesthesia**  
303 **gas machine on volume control mode ventilating two simulated patients with different lung compliances. (A)**  
304 With the ventilator on volume control, decreases in variable patient tidal volumes result in increases in tidal volumes  
305 delivered to the standard patient. This indicates that in volume control mode, patient ventilation circuits are  
306 interdependent, and changes in one patient effects the other. (B) The ratios of the patient's tidal volumes (standard  
307 patient/variable patient) per closure of the Vent-Lock FloRest with ventilators on volume control. (C) On ventilator  
308 volume control and with Vent-Lock FloRest closure, the changes in peak inspiratory pressure (PIP) of the standard  
309 patient and variable patient reflect that of tidal volume changes, while the ventilator reported PIP and P<sub>avg</sub> increase,  
310 and PEEP remains stable. (D) Vent-Lock FloRest was tested at Washington University in St. Louis using anesthesia  
311 gas machines. The FloRest can be used to control delivered tidal volumes to the variable patient on both pressure  
312 and volume control on anesthesia gas machines.

313

314           We replicated results using anesthesia gas machines (North American Drager Narkomed  
315 2a, Ardus Medical; GE Aestiva 5 7900, Datex Ohmeda) at an alternate test site (Washington  
316 University in St. Louis, St. Louis, Missouri, USA). The 1+1 circuit was tested with the Vent-  
317 Lock FloRest on the variable patient. On both pressure control and volume control settings, the  
318 Vent-Lock FloRest demonstrated control of tidal volume delivered to the variable patient with  
319 stable tidal volumes delivered to the standard patient. Pressure control allowed slightly greater  
320 range of control (Fig. 4D, reduction of 43.9% tidal volume at close, compared to 27.5%  
321 reduction of tidal volume at close with volume control)

### 322 ***Real-time pressure reporting with Vent-Lock manometer adaptors***

323           To facilitate continuous monitoring of pressures we designed a manometer adaptor that  
324 allows clinicians to either spot-check pressures or continuously monitor with the use of standard,  
325 disposable manometers such as those found on bag-valve-masks. The manometer adaptor can be  
326 added in the circuit at any point and is designed to accurately reflect breathing pressures, such as  
327 PIP and PEEP. We demonstrate that the manometer accurately reflects real-time pressures when  
328 incorporated in the circuit (Fig. 5A). In a 1+1 circuit with the ventilator on pressure control, the  
329 PEEP setting was incrementally increased, and associated ventilator detected PEEPs and Vent-  
330 Lock manometer reported pressures were recorded. The Vent-Lock manometer reported  
331 pressures were equivalent to the PEEPs (Figure 5B). We also conducted blind tests, where one  
332 researcher set the PEEP on the ventilator and a second researcher (blinded to ventilator PEEP  
333 settings) reported PEEP as reported by the Vent-Lock manometer. The second researcher  
334 consistently and accurately reported all test values between 0 cmH<sub>2</sub>O to 50 cmH<sub>2</sub>O, in 5 cmH<sub>2</sub>O  
335 increments, with total ten trials with no error.

336

337

338

339 (A)

340

341



342

343

344

345 (B)

(C)



346

347 **Fig. 5. Vent-Lock manometer adaptor.** (A) The Vent-Lock manometer adaptor is incorporated in the split circuit,

348 and allows for the attachment of disposable manometers, thus provides accurate, real time readings of pressures. (B)

349 When placed on the expiratory limb, the Vent-Lock manometer adaptor accurately reflects PEEP as set by the

350 ventilator and as reported by the ventilator. (C) We use the Vent-Lock manometer to report the PEEP of the variable

351 patient, as adjusted by the Vent-Lock FloRest on the expiratory limb. With closure of the FloRest, the PEEP

352 increases.

353




354

355 ***Vent-Lock 3DP Flow Restrictor (FloRest) in Swine***


356 Two domestic swine were anesthetized and ventilated using the Vent-Lock system with constant  
357 volume delivery. Swine were successfully ventilated for approximately four hours using a single  
358 ventilator. Initial calculated dynamic lung compliances were 50.3 and 48.1 ml/cm H<sub>2</sub>O for the  
359 standard and variable swine, respectively. Throughout the experiment, minimum and maximum  
360 dynamic compliance ranged from 50.3 to 244.5 and 37.9 to 87.1 ml/cm H<sub>2</sub>O for the standard and  
361 variable swine, respectively, reflecting the differences in tidal volumes those swine received  
362 during the flow restriction trial. Serial ABGs were monitored (Fig. 6) and initial shared ventilator  
363 settings were determined to be too high as both swine developed a respiratory alkalosis. At  
364 approximately two hours this was corrected and pH and paCO<sub>2</sub> were allowed to normalize for  
365 one hour. Vent settings were not changed following this equilibration. Over the next hour the  
366 Vent-Lock system was adjusted from fully open to fully closed, where air was still allowed to  
367 pass even when Vent-Lock is closed to prevent unintentional hypoventilation. Respiratory  
368 characteristics including tidal volume ratios, percent of total set tidal volume delivered,  
369 inspiratory pressure and tidal volume are presented in Fig. 7. While the tidal volume delivered to  
370 the variable swine decreased marginally, a substantial increase in tidal volume was noted to the  
371 standard swine (Fig. 7D), similar to what is seen in simulation center testing with ventilator on  
372 volume control mode. Arterial blood gas measurements demonstrated hyperoxia in both swine  
373 (Fig. 7C). A hypercarbic respiratory acidosis occurred in the variable swine (Figure 6A, B) as the  
374 Vent-Lock closure reached its final turn. Necropsy performed to assess for gross lung pathology  
375 showed no significant findings of all lung lobes.

376



377  
378

379 **Fig. 6. Serial Arterial Blood Gases were monitored throughout the experiment. (A) pH, (B) paCO<sub>2</sub>, and (C)**  
380 **paO<sub>2</sub> are all plotted as a function of time. (D) shows the number of turns from closed (with 6 turns being fully open)**  
381 **as a function of the time of the experiment. Note that the Vent-Lock system was reopened at approximately 2 hours**  
382 **due to development of hypercarbic alkalosis.**



383

384 **Fig. 7. Ventilatory parameters as a function of Vent-Lock aperture with 6 turns indicating fully open and**  
385 **zero fully closed.** The lowest turn plotted is 0.25 turns from fully closed. (A) Ratio of tidal volumes between the  
386 standard and variable swine. (B) Percent of currently set ventilator tidal volume measured in each swine. (C) Peak  
387 inspiratory pressure measured in each swine. (D) tidal volume measured in each swine.

388

## 389 DISCUSSION

390 In the face of the COVID-19 pandemic, the importance of ventilators in the treatment of  
391 COVID-19 patients and the tenuous global supply of chain has resulted in the urgent need to  
392 increase ventilator capacity. One such solution to lack of ventilators is the ability to use one  
393 ventilator to support multiple patients. Previously reported challenges include inability to

394 independently control flow and pressure to each patient, development of a closed system to  
395 prevent viral contamination, and continuous monitoring.

396 We used 3D-printing to rapidly prototype components of a ventilator splitter circuit that  
397 allows one ventilator or anesthesia gas machine to ventilate two patients. The circuit addresses  
398 aforementioned challenges and allows the clinician to control individual patient's pressures and  
399 volumes, in a closed system with bacterial filters to reduce viral contamination. 3D printing was  
400 selected as the prototyping and production modality due to rapid iterative production for research  
401 and development and on-demand manufacturing to meet urgent needs in context of  
402 biocompatible and sterilizable 3D printing materials. 3D printed components of the splitter  
403 circuit were designed to include ventilator splitters, manometer adaptors for continuous pressure  
404 monitoring and a flow restrictor to control tidal volumes and pressures.

405 The novel flow restrictor valve, Vent-Lock FloRest, is able to regulate tidal volumes to  
406 one patient while maintaining flow to another patient (Fig. 3), and control PEEP when placed on  
407 the expiratory limb with the manometer adaptor (Fig. 5). Design, research, and development was  
408 driven by creating an airtight valve that allows precise control by the clinician. We demonstrated  
409 that FloRest is compatible with multiple modes of ventilation strategies and anesthesia gas  
410 machines (Fig. 4D). Vent-Lock FloRest has demonstrated volume and pressure control by  
411 different physicians, using different mechanical ventilators or anesthesia gas machines, thus  
412 demonstrating potential compatibility with different ventilators and anesthesia gas machines.  
413 While the reproducibility of the Vent-Lock FloRest must be further investigated, this has  
414 important global scalability implications as we demonstrate potential compatibility and  
415 reproducibility not limited to make or type of ventilator or anesthesia gas machines, which may  
416 be more commonly available in developing countries.

417 Our studies reveal fundamental differences in tidal volume patterns with flow restriction  
418 with the ventilator in volume versus pressure mode. In pressure control, Vent-Lock FloRest  
419 allowed for reduction in delivered tidal volumes to the variable patient with stable volumes  
420 delivered to the standard patient (Fig. 3A). However, in volume control, reduction in delivered  
421 tidal volume to the variable patient resulted in a concomitant increase in tidal volume delivery to  
422 the standard patient. This pattern is expected due to the continuous delivered volume maintained  
423 by the machine; therefore, the Vent-Lock FloRest allowed regulation of the ratio, the  
424 standard/variable patient tidal volume ratio (Fig. 4B). This ratio pattern of control is seen in both  
425 ventilator volume control settings in the simulation center and replicated *in vivo* swine studies  
426 using anesthesia gas machines (Fig. 5). The variation in both patients may be difficult for  
427 clinicians to manage simultaneously. However, this ratio-based control delivered by Vent-Lock  
428 FloRest can be critical for splitting legacy ventilators or anesthesia gas machines that may only  
429 have volume control settings. One of the biggest challenges of splitting patients on ventilators is  
430 that air will preferentially travel to the patient with the highest baseline lung compliance  
431 resulting in unequal ventilation between the two patients. However, if Vent-Lock FloRest is  
432 placed on the patient with the highest baseline lung compliance (variable patient), air flow can be  
433 decreased, while simultaneously increasing air flow to the standard patient, until tidal volumes  
434 are equilibrated between the two. Consequently, while we demonstrate that flow restriction  
435 provides tidal volume control on ventilator pressure or volume control settings through different  
436 mechanisms. We emphasize that especially during emergency use settings, providers appreciate  
437 these differences in tidal volume control mechanisms, and select the setting most appropriate for  
438 patients and practice settings.

439           It is important to note that we validated ventilation multiplexing using anesthesia gas  
440 machines. Anesthesia gas machines have ventilation functions, and are widely available globally,  
441 even in developing countries. They are well suited to be repurposed for ICU ventilation in the  
442 face of ventilator shortages, and considerations for modification and usage settings have been  
443 addressed<sup>24</sup>. Our study provides follow up that in emergency situations, anesthesia gas machines  
444 can potentially be multiplexed to ventilate multiple patients using the Vent-Lock 3DP circuit.

445           In companion with the Vent-Lock FloRest, we also produced a manometer adaptor (Fig.  
446 5A) that can fit standardized disposable manometers commonly found in hospital settings, such  
447 as the Ambu Disposable Pressure Monitor (Ambu, Copenhagen, Denmark). When the  
448 manometer adaptor is placed in the Vent-Lock circuit, it allows for the continuous monitoring of  
449 pressures. This is particularly important as the ventilator reported values may not accurately  
450 reflect conditions of both patients and the rapidly changing states of both patients need to be  
451 monitored with subsequent adjustments to pressures. We do note that while the manometer  
452 adaptor with the manometer provides accurate readings (Fig. 5B), it is limited by the sensitivity  
453 of the manometers for clinical use. Furthermore, using the manometer and adapter allows for real  
454 time monitoring and facilitates individual control of PEEP with use of the Vent-Lock FloRest.  
455 When the FloRest is placed on the expiratory loop of the patient, restriction of airflow results in  
456 pressure increases between the patient and the FloRest, effectively functioning as PEEP (Fig.  
457 5C), which can then be reported by the manometer and adapter. This PEEP change established  
458 by FloRest and continuous monitoring does not affect the other patient split on the ventilator.  
459 Therefore, this is a critical asset of the circuit that allows for more patient-tailored PEEP therapy  
460 which is especially important in the treatment of patients with ARDS due to COVID-19 or other  
461 lung pathologies. While most PEEP valves currently rely on a spring-loaded control system, this

462 may be difficult to produce rapidly, especially via additive manufacturing. Our design  
463 demonstrates control of expiratory pressures through flow restriction. However, we do note  
464 challenges with FloRest in creating PEEP control, including that the PEEP was not changed until  
465 near complete occlusion of the valve, at which point additional turns resulted in rapid changes in  
466 PEEP (Fig. 5C). Consequently, we recognize that Vent-Lock FloRest requires further  
467 optimization prior to clinical usage, but exists as a proof-of-concept that PEEP control may be  
468 possible through a spring-less system.

469         Some limitations to our study include lack of human testing. While the swine in this  
470 study had similar lung compliances which allowed us to show that the device was able to restrict  
471 flow and that there is a finite tidal volume that is necessary and it is unknown how well this  
472 reflects human physiology. In addition to urgent need, challenges in continuous monitoring must  
473 be addressed prior to human studies. Future directions include developing a more rigorous  
474 continuous monitoring of flow rates and delivered tidal volumes to patients to facilitate  
475 adjustments of flow per FloRest. This is critical due to the dynamic lung physiologies of patients  
476 with ARDS and preventing barotrauma or under or over ventilation. Therefore, we recommend  
477 setting a target lung volume per patient, and monitoring via spirometry or airflow transducers,  
478 such as the ones used in our swine studies (SS11LB airflow transducer (Biopac; Goleta, CA)).  
479 Patient lung volumes and their oxygenation statuses should be spot checked with the spirometer  
480 or transducers and arterial blood gases. Lastly, we emphasize that ventilator multiplexing is only  
481 to be used in emergency situations after all alternatives have been exhausted. Despite our  
482 findings of improved ventilator multiplexing functions with Vent-Lock and Vent-Lock FloRest,  
483 additional studies are required to validate the safety and clinical considerations prior to

484 translation to human subjects. However, as future pandemics and disasters may exhaust standard-  
485 of-care for patient ventilation, Vent-Lock exists as a solution if “the other option is death”<sup>25</sup>.

486         During the COVID-19 pandemic, open sourcing has been used to expedite the creation of  
487 vital personal protective equipment (PPE) by sharing files for the creation of masks, face shields  
488 and ventilator adjuncts. Open sourcing and 3D printing have been proven to be helpful in the  
489 developing world by providing low cost, easy to use medical products, low cost construction of  
490 homes, water treatment devices and prosthetic limbs<sup>26</sup>. Thus, utilization of 3D printing to  
491 produce Vent-Lock circuit and Vent-Lock FloRest allows for the rapid, on-demand, on-site  
492 production to meet immediate needs. However, we recognize that our recommendation to use  
493 specific medical grade materials that are easily sterilized can limit production in the developing  
494 world. Further tests should be performed in varying material types to ensure accuracy in the  
495 printing process and translation into actual use. While it is promising that our materials have  
496 remained stable in humidified 40 °C for over 48 hours (fig. S3), we note that the material appears  
497 more brittle after multiple autoclave cycles, and thus further testing is required to ascertain  
498 stability across pressure gradients over weeks to months of use. Thus, we recommend single use  
499 of the devices until further investigation.

500         Additionally, we do recognize that the value of Vent-Lock circuit is also in its ability to  
501 be stored in preparation of emergency situations, such as disaster preparedness or in military  
502 combat zones, where ventilator shortages can be expected. In this case, we believe that while 3D  
503 printing production can meet initial interests, traditional manufacturing (such as injection  
504 molding), may be a more cost-effective and time-efficient approach to fulfil demand. While  
505 Vent-Lock circuit components are not currently optimized for traditional manufacturing, the  
506 designs can easily be modified to allow for this production modality, while still maintaining



507 access to 3D print for instances where manufacturing infrastructure is unavailable to produce this  
508 device. Consequently, we believe that open sourced 3D printing methodology of Vent-Lock  
509 production is appropriate for scalability in the face of urgent demand, such as the COVID-19  
510 pandemic, but can also be transitioned into traditional manufacturing.

511 In this study, we developed Vent-Lock, a ventilator or anesthesia gas machine splitter  
512 system with a flow restrictor (FloRest) that can modify flow rates per patient for patient tailored  
513 therapies. We provide proof-of-concept that two swine can be safely split using one anesthesia  
514 gas machine. While additional work is critical for the safe use of ventilator multiplexing, our  
515 data supports the feasible use of ventilator splitting for emergency situations, such as in face of  
516 COVID-19.

517

## 518 **MATERIALS AND METHODS**

### 519 **3D printing procedure.**

520 3D printing of the Vent-Lock splitters, flow regulators, and manometer adaptors were produced  
521 via stereolithography (Form 2, Form 3, or Form 3B, Formlabs) at 50 um layer resolutions, using  
522 surgical guide resin (Surgical Guide, Formlabs). Print files were generated by CAD drawings  
523 (SolidWorks, Dassault Systèmes) and converted into G-code using the printer's accompanying  
524 software package (PreForm, Formlabs). Support structures were minimized through design and  
525 generated using PreForm where needed. Components were oriented in such a way that crucial  
526 surfaces such as threads or O-ring ledges were not impacted by support structures. Prints were  
527 post-processed by washes (2 cycle with 15 min per cycle) in >99.5% isopropyl alcohol (CAS  
528 Number: 67-63-0, Sigma Aldrich), followed by air-drying at 22 °C for 30 minutes, and post-  
529 cured for 30 minutes with heat 60 °C for the Form 2 printer and 70 °C for the Form 3B printer at

530 405 nm of light (Form Cure, Formlabs). O-rings (E1000-212/AS568-212, O-Rings EPDM, FDA  
531 EPDM, Marco Rubber & Plastics, Seabrook, New Hampshire, USA) were added for improved  
532 sealing. Production via fused deposition modeling (FDM) (e3d, BigBox3D Ltd, Oxfordshire,  
533 UK; Little Monster, Tevo 3D Electronic Technology Co. Ltd, Zhanjiang, China) used PETG  
534 Filament (PETG 3D Printer Filament, FilaMatrix, Virginia, USA). Print settings were a 0.2mm  
535 layer height with 30% infill, nozzle temperature of 250 °C, and bed temperature of 70 °C;  
536 supports were generated from the build platform, with no interior supports.

### 537 **Sterilization Testing.**

538 3D-printed parts produced from surgical guide resin were sterilized by dry vacuum autoclave (Sr  
539 24C Adv-Plus<sup>TM</sup>, Consolidated Sterilizer Systems, Boston, Massachusetts, USA), 3 cycles at  
540 120.0 °C, 20 minutes sterilization time and 20 minutes dry time. Then, they were soaked in  
541 >99.5% isopropyl alcohol (CAS Number: 67-63-0, Sigma Aldrich) for 30 minutes, air-dried at  
542 22 °C for 30 minutes, and placed in an oven at 40 °C in humidified air for 48 hours  
543 (VO1824HPC, Lindberg/Blue M Vacuum Oven 127.4L, Thermo Scientific, Waltham, MA,  
544 USA). Particle count analyses were conducted using a particle counter (SOLAIR 3100,  
545 Lighthouse Worldwide Solutions), detecting sizes 0.3 to 10 microns, for 1-minute cycles, and  
546 performed for parts pre-autoclave, post-autoclave and post IPA wash, and humidified warm air  
547 exposure at 40 °C.

548 **Vent-Lock 1+n(1) circuit and components.** Vent-Lock circuits were assembled as depicted in  
549 Fig. 1. Vent-Lock 3DP splitters, flow regulator, and manometer adaptors were used. Commercial  
550 components include manometer (Ambu Disposable Pressure Manometer, Ambu, Copenhagen,  
551 Denmark), one-way valves (22F x 22M, REF 50245, Mallinckrodt Pharmaceuticals), disposable

552 bacteria filters (BSF104, Vincent Medical), and ventilator tubing (SKU: 999027588, Hudson  
553 Rci).

554 **Simulation Center Testing.** Vent-Lock 1+n(1) circuits were tested at the Johns Hopkins  
555 Medicine Simulation Center (JHMSC). The ventilator (Puritan Bennett 840 Ventilator System,  
556 Avante Health Solutions) was using pressure control mode of ventilation (Volume Ventilation  
557 Plus™, Avante Health Solutions) with additional settings detailed in fig. S4. Vent-Lock 1+1  
558 circuit was tested using test lungs simulating healthy lungs with variable compliances (Standard  
559 patient:  $R_p = 2$  cmH<sub>2</sub>O/L/s, RespiTrainer Advance, QuickLung, IngMar Medical; Variable  
560 patient:  $R_p = 50$  cmH<sub>2</sub>O/L/s, ASL 5000, IngMar Medical). Intrapulmonary data for both patients  
561 were collected; data included peak inspiratory pressures, tidal volumes, and peak end expiratory  
562 pressures. Five total values of tidal volume per data set were collected and averaged.  
563 Corresponding ventilator reported data was also recorded, including total expiratory volumes,  
564 peak inspiratory pressures, mean inspiratory pressures, and peak end expiratory pressures. Flow  
565 restrictors (#P20034 PVC SCH 40 ½-in FNPT Ball Valve; G300 Lead Free Brass Gate Valve;  
566 #P60SCPVC12 Stop and Waste Valve, American Valve, Greensboro, North Carolina, USA;  
567 Vent-Lock 3DP FloRest) were used to restrict the variable patient's inspiratory flow rate per the  
568 1+n(1) circuit (Fig. 1). Valve handles were turned at smallest increments permissible to close the  
569 valve and documented as % closure. Corresponding intrapulmonary data and ventilator reported  
570 values were collected per handle closure and standardized to values (volumes and pressures) of a  
571 fully open valve (reported as proportion of maximum, %).

572 In vitro studies were also conducted at the Washington University Simulation Center  
573 using two Datex-Ohmeda Aestiva anesthesia machines. One machine was set to deliver pressure  
574 control ventilation in a manner similar to that performed at Johns Hopkins. This machine was

575 connected in parallel to a 2L anesthesia bag reservoir and a second Datex-Ohmeda Aestiva  
576 machine that was set to spontaneous ventilation. The second machine served as a flow and  
577 volume sensor for the Vent-Lock 1+n(1) circuit.

578 ***In vivo* swine studies.** Experiments were performed in accordance with the Guide for the Care  
579 and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use  
580 Committee of Washington University School of Medicine (St. Louis, MO). Domestic swine (*Sus*  
581 *scrofa domestica*) were purchased from Oak Hill Genetics (Ewing, IL). The swine were  
582 females, 72 kg each, 5 months old, and were Landrace-cross swine. Swine were sedated with a  
583 telazol, ketamine, xylazine cocktail and intubated with a 7.0 endotracheal tube. Anesthesia was  
584 maintained with isoflurane. Femoral venous and arterial catheterization was performed. Standard  
585 ASA monitoring was maintained throughout the experiment. Swine were ventilated using a  
586 single ventilator (Dräger Narkomed 2A) with two circuits in parallel in an 1+n(1) configuration  
587 with cross-ventilation restricted by using one-way check valves. Ventilation was maintained with  
588 volume control. One swine was not flow-regulated and thus considered the standard patient,  
589 while the other had a Vent-Lock 3DP 4.0 connected in the inspiratory limb and thus considered  
590 the variable patient. Flow was measured at each expiratory limb with a SS11LB airflow  
591 transducer (Biopac; Goleta, CA). Flow data were collected at 2kHz using an MP36 data  
592 acquisition unit and BSL 4.1.3 software (Biopac; Goleta, CA). The spirometry data was then  
593 smoothed with a 0.25 sec wide moving median filter after removal of instrument noise below  
594 0.08 L/sec (determined by histogram inspection). The smoothed data was then numerically  
595 integrated to estimate respiratory tidal volume, and a first order numeric derivative was used to  
596 calculate the instantaneous respiratory rate. The noise floor for the integrated volume was  
597 determined by histogram inspection resulting in a threshold of 90 mL. The anesthesia record and

598 the spirometry results were then aligned using common timestamps. All breaths spontaneously  
599 initiated by the swine (identified by respiratory rates more than 30% away from the ventilator set  
600 point) were removed from analysis. The mean and standard deviation for each anesthesia record  
601 entry were calculated for respiratory rate, tidal volume, minute ventilation, and lung compliance.  
602 All of the described analysis was performed using a custom MATLAB script (MATLAB 2019b,  
603 The MathWorks, Inc., Natick, MA)]. Arterial and venous blood gas data were collected 15  
604 minutes following any changes to the Vent-Lock 3DP device. Following the procedure, swine  
605 were euthanized with an overdose (~150mg/kg) of supersaturated potassium chloride IV while  
606 under anesthesia. Necropsy was performed to assess for any gross lung pathology.

607

## 608 REFERENCES

- 609 1. Poston, J. T., Patel, B. K. & Davis, A. M. Management of Critically Ill Adults With  
610 COVID-19. *JAMA* **323**, 1839–1841 (2020).
- 611 2. GlobalData. 880,000 global ventilator shortage can only be met by new simple design  
612 requiring minimal operator training time, says GlobalData.  
613 [https://www.globaldata.com/880000-global-ventilator-shortage-can-only-be-met-by-new-](https://www.globaldata.com/880000-global-ventilator-shortage-can-only-be-met-by-new-simple-design-requiring-minimal-operator-training-time-says-globaldata/)  
614 [simple-design-requiring-minimal-operator-training-time-says-globaldata/](https://www.globaldata.com/880000-global-ventilator-shortage-can-only-be-met-by-new-simple-design-requiring-minimal-operator-training-time-says-globaldata/) (2020).
- 615 3. Oshitani, H., Kamigaki, T. & Suzuki, A. Major Issues and Challenges of Influenza  
616 Pandemic Preparedness in Developing Countries. *Emerg. Infect. Dis. J.* **14**, 875 (2008).
- 617 4. Murray, C. J., Lopez, A. D., Chin, B., Feehan, D. & Hill, K. H. Estimation of potential  
618 global pandemic influenza mortality on the basis of vital registry data from the 1918-20  
619 pandemic: a quantitative analysis. *Lancet* **368**, 2211–2218 (2006).
- 620 5. Maclean, R. & Marks, S. 10 African Countries Have No Ventilators. That is only part of

- 621 the problem. *The New York Times*
- 622 <https://www.nytimes.com/2020/04/18/world/africa/africa-coronavirus-ventilators.html>
- 623 (2020).
- 624 6. Bartsch, S. M. *et al.* The Potential Health Care Costs And Resource Use Associated With
- 625 COVID-19 In The United States. *Health Aff.* 10.1377/hlthaff (2020)
- 626 doi:10.1377/hlthaff.2020.00426.
- 627 7. Ranney, M. L., Griffeth, V. & Jha, A. K. Critical supply shortages - The need for
- 628 ventilators and personal protective equipment during the Covid-19 pandemic. *New*
- 629 *England Journal of Medicine* (2020) doi:10.1056/NEJMp2006141.
- 630 8. Xu, S. & Li, Y. Beware of the second wave of COVID-19. *Lancet* **395**, 1321–1322
- 631 (2020).
- 632 9. SCCM Rapid Cycle 3 Response Summary. *Society of Critical Care Medicine* (2020).
- 633 10. Sebastian, D. GM to Make 30,000 Ventilators for National Stockpile in \$489 Million
- 634 Contract. *Wall Street Journal* [https://www.wsj.com/articles/gm-to-make-30-000-](https://www.wsj.com/articles/gm-to-make-30-000-ventilators-for-national-stockpile-in-489-million-contract-11586347203)
- 635 [ventilators-for-national-stockpile-in-489-million-contract-11586347203](https://www.wsj.com/articles/gm-to-make-30-000-ventilators-for-national-stockpile-in-489-million-contract-11586347203) (2020).
- 636 11. United States Resource Availability for COVID-19. *The Society of Critical Care Medicine*
- 637 <https://sccm.org/Blog/March-2020/United-States-Resource-Availability-for-COVID-19>
- 638 (2020).
- 639 12. Mirchandani, P. Health Care Supply Chains: COVID-19 Challenges and Pressing Actions.
- 640 *Ann. Intern. Med.* (2020).
- 641 13. Neyman, G. & Irvin, C. B. A Single Ventilator for Multiple Simulated Patients to Meet
- 642 Disaster Surge. *Acad. Emerg. Med.* **13**, 1246–1249 (2006).
- 643 14. Menes, K., Tintinalli, J. & Plaster, L. How One Las Vegas ED Saved Hundreds of Lives

- 644 After the Worst Mass Shooting in U.S. History. *Emergency Physicians Monthly*  
645 <https://epmonthly.com/article/not-heroes-wear-capas-one-las-vegas-ed-saved-hundreds->  
646 [lives-worst-mass-shooting-u-s-history/](https://epmonthly.com/article/not-heroes-wear-capas-one-las-vegas-ed-saved-hundreds-lives-worst-mass-shooting-u-s-history/) (2017).
- 647 15. Chatburn, R. L., Branson, R. D. & Hatipoğlu, U. Multiplex Ventilation: A Simulation-  
648 based Study of Ventilating Two Patients with One Ventilator. *Respir. Care*  
649 *respcare.07882* (2020) doi:10.4187/respcare.07882.
- 650 16. Consensus Statement on Multiple Patients Per Ventilator. *The Society of Critical Care*  
651 *Medicine* [https://www.sccm.org/Disaster/Joint-Statement-on-Multiple-Patients-Per-](https://www.sccm.org/Disaster/Joint-Statement-on-Multiple-Patients-Per-Ventilato)  
652 [Ventilato](https://www.sccm.org/Disaster/Joint-Statement-on-Multiple-Patients-Per-Ventilato) (2020).
- 653 17. Srinivasan, S. *et al.* Individualized System for Augmenting Ventilator Efficacy (iSAVE):  
654 A Rapidly deployable system to expand ventilator capacity. *bioRxiv* 2020.03.28.012617  
655 (2020) doi:10.1101/2020.03.28.012617.
- 656 18. *Impact of the Global Medical Supply Chain on SNS Operations and Communications.*  
657 *Impact of the Global Medical Supply Chain on SNS Operations and Communications*  
658 (2018). doi:10.17226/25149.
- 659 19. Boyson, S. A defining moment in our medical supply chain crisis. *The Hill*  
660 [https://thehill.com/opinion/international/490963-a-defining-moment-in-our-medical-](https://thehill.com/opinion/international/490963-a-defining-moment-in-our-medical-supply-chain-crisis)  
661 [supply-chain-crisis](https://thehill.com/opinion/international/490963-a-defining-moment-in-our-medical-supply-chain-crisis) (2020).
- 662 20. Attaran, M. & Attaran, M. 3D Printing Role in Filling the Critical Gap in the Medical  
663 Supply Chain during COVID-19 Pandemic. *Am. J. Ind. Bus. Manag.* **10**, 988–1001  
664 (2020).
- 665 21. Zadpoor, A. A. Design for additive bio-manufacturing: From patient-specific medical  
666 devices to rationally designed meta-biomaterials. *International Journal of Molecular*

- 667 *Sciences* (2017) doi:10.3390/ijms18081607.
- 668 22. FDA. Technical Considerations for Additive Manufactured Devices Draft Guidance for  
669 Industry and Food and Drug Administration Staff. *Clim. Chang. 2013 - Phys. Sci. Basis*  
670 (2016) doi:10.1017/CBO9781107415324.004.
- 671 23. Ishack, S. & Lipner, S. R. Applications of 3D Printing Technology to Address COVID-19  
672 Related Supply Shortages. *Am. J. Med.* (2020) doi:10.1016/j.amjmed.2020.04.002.
- 673 24. APSF/ASA. APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators.  
674 *Am. Soc. Anesthesiol.* (2020).
- 675 25. Rosenthal, B. M., Pinkowski, J. & Goldstein, J. ‘The Other Option Is Death’: New York  
676 Starts Sharing of Ventilators. *The New York Times*  
677 <https://www.nytimes.com/2020/03/26/health/coronavirus-ventilator-sharing.html> (2020).
- 678 26. Ibrahim, A. M. S. *et al.* Three-dimensional Printing in Developing Countries. *Plast.*  
679 *Reconstr. Surg. – Glob. Open* **3**, (2015).

680

681 **ACKNOWLEDGEMENTS** We would like to thank the Johns Hopkins Medicine Simulation  
682 Center Jordan Duval-Arnould, Julie Perretta, and Joe Dwyer for use of the simulation center; Dr.  
683 Thao (Vicky) Nguyen, Dr. Joe Katz for their advice; Dr. Adam Sapirstein for their medical  
684 expertise; Dr. Sarah Clever for her support; the Johns Hopkins Applied Physics Lab for guidance  
685 and advice; Dr. Gerald Brandacher and Yi-nan Guo for use of their autoclave; Gregory Bova for  
686 loan of his particle counter; and Dr. Arun Agrawal and Azra Horowitz for their advice on  
687 ventilator splitting. The authors acknowledge financial support from the Johns Hopkins  
688 University President’s Response to COVID-19 Fund, the Start-Up Fund from the Whiting  
689 School of Engineering at Johns Hopkins University, support from the Department of Civil and



690 Systems Engineering and Johns Hopkins Center for Additive Manufacturing and Architected  
691 Materials, and the National Science Foundation (DMREF-1628974). JU acknowledges financial  
692 support from the U.S. Army Research Office (ARO) sponsored NDSEG Fellowship program and  
693 AT acknowledges support by a NASA Space Technology Research Fellowship.

694

695 **COMPETING INTERESTS** Authors Xun, Shallal, Unger, Tao, Torres, Vladimirov, Frye,  
696 Singhala, Horne, Yesantharao, Kim, Talcott, Montana, Winters, Frisella, Kushner, Guest, Kang,  
697 and Caffrey have no relevant disclosures. Dr. Burke receives research funding from the  
698 International Anesthesiology Research Society Mentored Research Award. Dr. Sacks receives  
699 unrestricted research funding from ViOptix Inc., and is co-founder of LifeSprout Inc.

700

701 **AUTHOR CONTRIBUTIONS** HX, JKG, SHK, and JC conceived the research. HX, CS, JU,  
702 RHT, AT, MV, JF, MS, BW, JKG, SHK, and JC contributed to engineering designs and  
703 production. HX, CS, JU, RT, AT, MV, JF, MS, PY, BSK, BW, JKG, SHK, and JC contributed to  
704 experimental design and testing in the JHMSC. BH and JF contributed to communications and  
705 graphic design. BB, MM, MT, MF, BK, and JMS contributed to simulation center testing and  
706 swine studies at Washington University in St. Louis. JKG, SHK, and JC supervised the research.  
707 All authors contributed to the drafting and editing of this manuscript.

708

## 709 **FIGURE LEGENDS**

710 **Fig. 1. Vent-Lock ventilator multiplexing 1+n(1) circuit and 3DP components.** Our 1+n(1)  
711 circuit proposes having a standard patient with minimal features, thus are ventilated per  
712 ventilator settings. Additional patients added to the circuit will be considered n(1), and will have

713 variable flow and PEEP as controlled by circuit components. Please note that all patients,  
714 regardless of standard or variable, have one-way (check) valves and filters.

715  
716 **Figure 2. Design and performance of 3DP Flow Restrictor (FloRest).** (A) Vent-Lock 3DP  
717 Flow Restrictor (FloRest) contains three components. The O-ring between the cap and full-  
718 height threaded needle interface at the top of the chamber to maintain air-tight seals. Both ends  
719 of Vent-Lock FloRest are male ISO fittings to ensure connection to ventilator tubing. (B) Testing  
720 with a ventilator on pressure control using simulation lungs at varying compliances demonstrates  
721 that Vent-Lock FloRest provides more control options than commercial ball valves and gate  
722 valves, characterized by more available data points corresponding with different tidal volumes  
723 delivered.

724  
725 **Fig. 3. Pressure control mode: testing of Vent-Lock ventilator multiplexor with a ventilator**  
726 **on pressure control mode ventilating two simulated patients with different lung**  
727 **compliances.** (A) When used with a ventilator on pressure control, Vent-Lock FloRest is capable  
728 of controlling tidal volumes delivered to the variable patient per turn, with no change to tidal  
729 volumes delivered to the standard patient. (B) PIP of the standard patient remains stable, despite  
730 changing PIP of the variable patient. Using a ventilator on pressure control, we determine the  
731 changes in standard and variable patient breathing pressures with closure of the Vent-Lock  
732 FloRest, and the ventilator reported pressures. The positive inspiratory pressure (PIP) of the  
733 variable patient decreases with closure, while the standard patient PIP, and ventilator reported  
734 average breathing pressures ( $P_{avg}$ ), and PEEP remain constant. We do note an increase in the  
735 ventilator reported PIP. (C) With the ventilator on pressure control, changes to tidal volume

736 delivered to patients using Vent-Lock FloRest demonstrates a corresponding change in peak  
737 inspiratory pressures (PIP).

738

739 **Figure 4. Volume control mode: testing of Vent-Lock ventilator multiplexer with a**  
740 **ventilator or anesthesia gas machine on volume control mode ventilating two simulated**  
741 **patients with different lung compliances.** (A) With the ventilator on volume control, decreases  
742 in variable patient tidal volumes result in increases in tidal volumes delivered to the standard  
743 patient. This indicates that in volume control mode, patient ventilation circuits are  
744 interdependent, and changes in one patient effects the other. (B) The ratios of the patient's tidal  
745 volumes (standard patient/variable patient) per closure of the Vent-Lock FloRest with ventilators  
746 on volume control. (C) On ventilator volume control and with Vent-Lock FloRest closure, the  
747 changes in peak inspiratory pressure (PIP) of the standard patient and variable patient reflect that  
748 of tidal volume changes, while the ventilator reported PIP and  $P_{avg}$  increase, and PEEP remains  
749 stable. (D) Vent-Lock FloRest was tested at Washington University in St. Louis using anesthesia  
750 gas machines. The FloRest can be used to control delivered tidal volumes to the variable patient  
751 on both pressure and volume control on anesthesia gas machines.

752 **Fig. 5. Vent-Lock manometer adaptor.** (A) The Vent-Lock manometer adaptor is incorporated  
753 in the split circuit, and allows for the attachment of disposable manometers, thus provides  
754 accurate, real time readings of pressures. (B) When placed on the expiratory limb, the Vent-Lock  
755 manometer adaptor accurately reflects PEEP as set by the ventilator and as reported by the  
756 ventilator. (C) We use the Vent-Lock manometer to report the PEEP of the variable patient, as  
757 adjusted by the Vent-Lock FloRest on the expiratory limb. With closure of the FloRest, the  
758 PEEP increases.

759 **Fig. 6. Serial Arterial Blood Gases were monitored throughout the experiment.** (A) pH, (B)  
760  $\text{paCO}_2$ , and (C)  $\text{paO}_2$  are all plotted as a function of time. (D) shows the number of turns from  
761 closed (with 6 turns being fully open) as a function of the time of the experiment. Note that the  
762 Vent-Lock system was reopened at approximately 2 hours due to development of hypercarbic  
763 alkalosis.

764 **Fig. 7. Ventilatory parameters as a function of Vent-Lock aperture with 6 turns indicating**  
765 **fully open and zero fully closed.** The lowest turn plotted is 0.25 turns from fully closed. (A)  
766 Ratio of tidal volumes between the standard and variable swine. (B) Percent of currently set  
767 ventilator tidal volume measured in each swine. (C) Peak inspiratory pressure measured in each  
768 swine. (D) tidal volume measured in each swine.

## 769 SUPPLEMENTARY MATERIALS

770 Fig. S1. *De novo* ventilator circuit components produced via 3D printing

771 Fig. S2. Air-tightness tests of the Vent-Lock FloRest.

772 Fig. S3. Design files for Vent-Lock splitters, needle valve, and manometer adaptor.

773 Fig. S4. Tests of tidal volume control with and without O-rings.

774 Fig. S5. Comparisons of Vent-Lock FloRest performances depending on materials.

775 Table S1. The biodurability and sterilization conditions.

776 Table S2. Ventilator settings on 840 Ventilator System, Nellcor Puritan Bennett.

777 Mov S1. Leaky bubble test demonstrates Vent-Lock FloRest is airtight

778 Data S1. STL print files of Vent-Lock splitter, FloRest, and manometer adaptor

779 Data S2. MATLAB code used to analyze swine data

780

781

782

783

784

785

786

787

788